Tina Nova has served as President and Chief Executive Officer (CEO) of Molecular Stethoscope, a diagnostics company, since 2015, and previously was Senior Vice President and General Manager of Illumina’s oncology business unit. Tina was a co-founder of Genoptix, a medical laboratory diagnostics company, and served as its President through 2014. She also served as the company’s CEO and as a member of its board of directors from 2000 until Novartis AG acquired Genoptix in 2011.
Tina was a co-founder of Nanogen, a provider of molecular diagnostic tests, and served as its Chief Operating Officer and President from 1994 to 2000. She previously served as Chief Operating Officer of Selective Genetics, a biotechnology company, and held various positions with Ligand Pharmaceuticals and Hybritech.
Tina serves as the Chair of the Board of Directors for Arena Pharmaceuticals and as a member of the Board of Directors of Veracyte, a diagnostics company. Tina received a B.S. in Biological Sciences from the University of California, Irvine, and a Ph.D. in Biochemistry from the University of California, Riverside.